The US Food and Drug Administration on Friday approved Moderna's respiratory syncytial virus (RSV) vaccine for older adults—marking the first time any mRNA shot has been authorized against a disease other than COVID-19.
A hypothetical respiratory syncytial virus (RSV) vaccine may be cost effective in the elderly Dutch population who are at high risk of contracting RSV infections. Results of the modelling study showed that it would not be cost effective to vaccinate the entire Dutch population aged ≥ 60 ...
"RSV can be very serious for those who are more vulnerable, such as older adults. In recent years, we've seen an increase in those aged 75 years and over being hospitalized for RSV. That's why we're asking all those who are eligible for the RSV vaccine to take up the offer to pro...
Vaccine makers are still studying when seniors might need to come back for a booster dose of RSV vaccine in the coming years. They also have yet to decide on a final price, further complicating broader recommendations. GSK said their vaccine could be priced between $200 and $295 per dose, ...
查看详细目录内容或报告样本链接申请:https://www.qyresearch.com.cn/reports/4326352/respiratory-syncytial-virus-vaccine-for-the-elderly 老年人用呼吸道合胞病毒(RSV)疫苗报告主要研究范围有: 第1章:报告统计范围、老年人用呼吸道合胞病毒(RSV)疫苗产品细分及主要的下游市场,行业背景、发展历史、现状及趋势等 ...
如您需要查看完整版(目录+图表)或申请报告样本可点击链接:https://www.qyresearch.com.cn/reports/4326349/respiratory-syncytial-virus-vaccine-for-the-elderly 老年人用呼吸道合胞病毒(RSV)疫苗报告主要研究企业名单如下,也可根据客户要求增加目标企业:GSK、Pfizer、Moderna、第一三共、Icosavax、Sanofi、蓝湖生物技...
National Foundation for Infectious Diseases. Respiratory Syncytial Virus. Accessed May 2023. Available at:www.nfid.org/infectious-disease/rsv/ Falsey AR, et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005; 352:1749-1759. ...
These findings coincide with the development of a vaccine for pregnant individuals, while the CDC deliberates on an RSV vaccine for older adults; important given RSV is a leading cause of lower respiratory tract infections in infants and can cause serious illness in both infants and the elderly ...
Phil Dormitzer, chief of vaccine research and development for GSK, formerly known as GlaxoSmithKline. RSV is a cold-like nuisance for most people but it can be life-threatening for the very young, the elderly and people with certain high-risk health problems. It can impede babies’ breathing...
Given that RSV is a significant health concern, particularly in vulnerable populations like infants and the elderly, it would be important to make an RSV vaccine more accessible and more affordable. JS: It is likely that RSV vaccination will focus initially on the paediatric population, as epidemi...